H+A的百奥赛图募资的随意性与对科研人员卸磨杀驴来美化报表?从而由22年23年的连续亏损近10亿实现24年的盈利3000多万?一面是A+H上市的光环,一面是大规模人员优化的现实,百奥赛图扭亏为盈的奇迹背后,藏着多少“研发耗材”的心酸故事?就在本周,百奥赛图这家“临床前CRO及生物技术企业”即将迎来上交所IPO审核的“大考”。从2023年6月申报至今,两年多的等待时间对于IPO来说算不上快,但这家...
Source LinkH+A的百奥赛图募资的随意性与对科研人员卸磨杀驴来美化报表?从而由22年23年的连续亏损近10亿实现24年的盈利3000多万?一面是A+H上市的光环,一面是大规模人员优化的现实,百奥赛图扭亏为盈的奇迹背后,藏着多少“研发耗材”的心酸故事?就在本周,百奥赛图这家“临床前CRO及生物技术企业”即将迎来上交所IPO审核的“大考”。从2023年6月申报至今,两年多的等待时间对于IPO来说算不上快,但这家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.